Liver carcinoma
|
0.300 |
Therapeutic
|
disease |
RGD |
PCNA index decreased from 80 in HCC rats to 32 after boron treatment.In the control group, it was 20.
|
23219601 |
2013 |
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
PCNA was co-localized with active caspase 3 protein expression in HBx zebrafish liver samples and human HBV positive HCC samples by double fluorescence immunostaining.
|
23499292 |
2013 |
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
PCNA messenger RNA (mRNA) levels progressively increased from normals to CAH and to cirrhotic patients, and persisted at a high level in the tumorous and in the nontumorous area of HCC subjects, thus showing that the increase of IGF-II transcripts in CAH and cirrhosis is accompanied by an activation of cell mitosis in these samples.
|
8675143 |
1996 |
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
A concomitant decline in immunohistochemically detected number of the proliferating cell nuclear antigen (PCNA), a cell proliferation marker, in the HCC liver, further confirmed anti-cell proliferative role of Fisetin during HCC growth <i>in vivo</i>.
|
29298655 |
2018 |
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
A positive correlation was established between the levels of AIB1 protein and PCNA protein in HCC, suggesting that AIB1 may contribute to HCC cell proliferation.
|
20305690 |
2010 |
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Among the various types of cell-cycle regulators, p16 and p27 are frequently inactivated in HCC and are considered to be potent tumor suppressors. p16, a G1-specific cell-cycle inhibitor that prevents the association of cyclindependent kinase (CDK) 4 and CDK6 with cyclin D1, is frequently inactivated in HCC via CpG methylation of its promoter region. p16 may be involved in the early steps of hepatocarcinogenesis, since p16 gene methylation has been detected in subsets of pre-neoplastic liver cirrhosis patients. p27, a negative regulator of the G1-S phase transition through inhibition of the kinase activities of Cdk2/cyclin A and Cdk2/cyclin E complexes, is now considered to be an adverse prognostic factor in HCC.
|
18350604 |
2008 |
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Antisense long non-coding RNA PCNA-AS1 promotes tumor growth by regulating proliferating cell nuclear antigen in hepatocellular carcinoma.
|
24704293 |
2014 |
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Beclin-1 expression in HCC tissues was negatively correlated with the expression of PCNA, NET-1, and anti-apoptotic protein Bcl-2, but positively correlated with pro-apoptotic protein Bax expression.
|
31128017 |
2019 |
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Consistent with these results, the expression of SRC-1 was positively correlated with PCNA expression in human HCC specimens, and the expression levels of c-Myc in SRC-1-positive HCC specimens were higher than in SRC-1-negative HCC specimens.
|
26082485 |
2015 |
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Functionally, PCNAP1 or PCNA remarkably enhanced HBV replication and accelerated the growth of HCC <i>in vitro</i> and <i>in vivo</i>.
|
31410212 |
2019 |
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Further evidence at the molecular level indicated that celecoxib down-regulated the expression of phospho-ERK (Thr202/Tyr204) and proliferating cell nuclear antigen (PCNA) in the HCC mice.
|
30182439 |
2019 |
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Furthermore, we found that TFP in vivo could effectively restrict the angiogenesis and tumor growth with reduced expression of VEGF, Bcl-2, and PCNA, and increased the nuclear localization of FOXO1, which indicated its antitumor role in HCC.
|
28876084 |
2017 |
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
In 6 of 12 HCCs and in cell lines, we found three major PCNA acidic forms, corresponding to monomers, probably dimers and trimers, and a basic isoform.
|
18521065 |
2008 |
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In addition, we inhibited DNMT1 using siRNA in the SMMC-7721 HCC cell line and found depletion of DNMT1 suppressed cells growth independent of expression of proliferating cell nuclear antigen (PCNA), even in HCC cell lines where DNMT1 was stably decreased.
|
19399937 |
2009 |
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In an attempt to evaluate its prognostic significance and clinicopathologic correlation in patients with hepatocellular carcinoma (HCC), the proliferative activity was studied using immunohistochemical staining with monoclonal antibody to PCNA.
|
7513246 |
1994 |
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
In contrast, there was no correlation between c-myc overexpression, found in 19 out of 40 HCC (47.5%), and histological grading of HCC or PCNA labeling index.
|
8104947 |
1993 |
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
In double-labelling experiments, PCNA and HDV RNA staining did not co-localize, with the exception of two of three cirrhotic tissues associated with HCC, where the association between the two markers was statistically significant.
|
9097264 |
1997 |
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In this study, we examined the molecular mechanisms by which naringenin inhibited NDEA-induced hepatocellular carcinoma in rats by analysing the expression patterns of proliferating cell nuclear antigen, Bcl-2, NF-κB, VEGF and MMP-2/9.
|
23172681 |
2013 |
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In vivo, hepatocytes isolated from HCC tumor tissue and matching paracancerous tissue in DEN-treated CCR10 KO mice showed significantly lower Akt phosphorylation and PCNA expression relative to WT hepatocytes.
|
29445190 |
2018 |
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Integrated gene expression data revealed highest expression of proliferation-related CTGF, c-MYC, and PCNA, and lowest expression of BHMT, DMBT1, DUSP1, GADD45g, and GNMT, in more aggressive rat and human HCC.
|
22434528 |
2012 |
Liver carcinoma
|
0.300 |
PosttranslationalModification
|
disease |
BEFREE |
Interestingly, TFF1-positive cancer cells showed a staining pattern contradictory to that of proliferating cell nuclear antigen (PCNA), and aberrant DNA hypermethylation in TFF1 promoter lesions was detected in HCC samples, indicating the tumor-suppressive role of TFF1.
|
31733149 |
2019 |
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Moreover, enhanced expression of NPM in HCC correlated with the level of PCNA (R(2)=0.5639) and with the clinical prognostic parameters such as serum alpha fetal protein level, tumour pathological grading, and liver cirrhosis (P<0.05).
|
17245342 |
2007 |
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Our present study confirmed moderate hyperthermia treatment can promote the proliferation, migration and invasion of hepatocellular carcinoma (HCC) cells, which was evidenced by the results that moderate hyperthermia induced up regulation of proliferating cell nuclear antigen (PCNA) and matrix metalloproteinase-2 (MMP-2).
|
29894725 |
2018 |
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our study investigated the effects of YSL on human hepatocellular carcinoma and cyclin, and explored its antitumor mechanism in vitro.
|
19491661 |
2009 |
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
P53 Ser15-P is associated with poor outcomes in patients with HCC, and this prognostic marker is useful for predicting the survival of patients with PCNA-positive HCC.
|
30881947 |
2019 |